These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 19287973)

  • 21. Hoxb7 inhibits transgenic HER-2/neu-induced mouse mammary tumor onset but promotes progression and lung metastasis.
    Chen H; Lee JS; Liang X; Zhang H; Zhu T; Zhang Z; Taylor ME; Zahnow C; Feigenbaum L; Rein A; Sukumar S
    Cancer Res; 2008 May; 68(10):3637-44. PubMed ID: 18463397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells.
    Croci S; Nicoletti G; Landuzzi L; Palladini A; Chiarini F; Nanni P; Lollini PL; De Giovanni C
    Oncol Rep; 2007 Aug; 18(2):451-6. PubMed ID: 17611670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12.
    Nanni P; Nicoletti G; De Giovanni C; Landuzzi L; Di Carlo E; Iezzi M; Ricci C; Astolfi A; Croci S; Marangoni F; Musiani P; Forni G; Lollini PL
    Int J Cancer; 2003 Jun; 105(3):384-9. PubMed ID: 12704673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alcohol promotes mammary tumor development via the estrogen pathway in estrogen receptor alpha-negative HER2/neu mice.
    Wong AW; Dunlap SM; Holcomb VB; Nunez NP
    Alcohol Clin Exp Res; 2012 Apr; 36(4):577-87. PubMed ID: 21981381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
    Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
    Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Promotion of breast cancer by beta-hexachlorocyclohexane in MCF10AT1 cells and MMTV-neu mice.
    Wong PS; Matsumura F
    BMC Cancer; 2007 Jul; 7():130. PubMed ID: 17640349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2/neu.
    Bergman I; Griffin JA; Gao Y; Whitaker-Dowling P
    Int J Cancer; 2007 Jul; 121(2):425-30. PubMed ID: 17354238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice.
    Ma Z; Parris AB; Xiao Z; Howard EW; Kosanke SD; Feng X; Yang X
    J Exp Clin Cancer Res; 2017 Jan; 36(1):6. PubMed ID: 28061785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Involvement of Notch1 in the development of mouse mammary tumors.
    Diévart A; Beaulieu N; Jolicoeur P
    Oncogene; 1999 Oct; 18(44):5973-81. PubMed ID: 10557086
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro and in vivo antisense-mediated growth inhibition of a mammary adenocarcinoma from MMTV-neu transgenic mice.
    Sacco MG; Barbieri O; Piccini D; Noviello E; Zoppé M; Zucchi I; Frattini A; Villa A; Vezzoni P
    Gene Ther; 1998 Mar; 5(3):388-93. PubMed ID: 9614559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Wnt-1 is dominant over neu in specifying mammary tumor expression profiles.
    Huang S; Podsypanina K; Chen Y; Cai W; Tsimelzon A; Hilsenbeck S; Li Y
    Technol Cancer Res Treat; 2006 Dec; 5(6):565-71. PubMed ID: 17121432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autocrine PDGFR signaling promotes mammary cancer metastasis.
    Jechlinger M; Sommer A; Moriggl R; Seither P; Kraut N; Capodiecci P; Donovan M; Cordon-Cardo C; Beug H; Grünert S
    J Clin Invest; 2006 Jun; 116(6):1561-70. PubMed ID: 16741576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity.
    Sriram R; Lo V; Pryce B; Antonova L; Mears AJ; Daneshmand M; McKay B; Conway SJ; Muller WJ; Sabourin LA
    Breast Cancer Res; 2015 Jan; 17(1):7. PubMed ID: 25592291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
    Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.
    Landis MD; Seachrist DD; Montañez-Wiscovich ME; Danielpour D; Keri RA
    Oncogene; 2005 Aug; 24(33):5173-90. PubMed ID: 15897883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice.
    Peirce SK; Chen WY
    Oncogene; 2004 Feb; 23(6):1248-55. PubMed ID: 14647416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects.
    Yang YA; Dukhanina O; Tang B; Mamura M; Letterio JJ; MacGregor J; Patel SC; Khozin S; Liu ZY; Green J; Anver MR; Merlino G; Wakefield LM
    J Clin Invest; 2002 Jun; 109(12):1607-15. PubMed ID: 12070308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis.
    Rudolph-Owen LA; Chan R; Muller WJ; Matrisian LM
    Cancer Res; 1998 Dec; 58(23):5500-6. PubMed ID: 9850086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice.
    Wolpoe ME; Lutz ER; Ercolini AM; Murata S; Ivie SE; Garrett ES; Emens LA; Jaffee EM; Reilly RT
    J Immunol; 2003 Aug; 171(4):2161-9. PubMed ID: 12902523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.
    Tran T; Diniz MO; Dransart E; Gey A; Merillon N; Lone YC; Godefroy S; Sibley C; Ferreira LC; Medioni J; Oudard S; Johannes L; Tartour E
    Clin Cancer Res; 2016 Aug; 22(16):4133-44. PubMed ID: 27006496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.